PainReform Ltd (PRFX): Total Asset Value of Company

Graphic logo of PainReform Limited (PRFX)

PainReform Ltd. (PRFX) is currently focusing on the independent market launch of its patented analgesic by developing direct sales to clinics. Demand for such medications remains stable and independent of economic crises, rendering the model resilient. The price visualization on GURU.Markets, which assists in the basic asset valuation, shows total assets at 15.13, supporting the business of creating affordable, high-margin injections.

PainReform Ltd. (PRFX) Company Total Assets: for the period 07/04/2022 - 10/28/2026

Comprehensive metric breakdowns and analytics for PainReform Limited (PRFX)

- price and consensus price forecast:
Share Price painreform.com|PRFX - Price Target Chart
- market capitalization data:
Market Valuation PainReform Corp|PRFX - Enterprise Value
- book capitalization data:
Accounting Value of a Share PainReform|PRFX - Book Capitalization|Market Capitalization to Book Value Ratio painreform.com|PRFX - Aggregate Company Assets
- debt and liquidity data:
All Debt to Shareholders' Equity Ratio PainReform Ltd.|PRFX - Long-Term Debt to Equity|Short-Term Debt to Equity Ratio PainReform Corp|PRFX - Company Aggregate Debts|Debts to Book Capitalization PainReform Corp
Fundamental valuation:PRFX, painreform.com
Finished products of PainReform Ltd.

For PainReform Ltd., which focuses on biopolymers for analgesic delivery, total assets reflect the aggregate volume of resources calculated reverse-engineered through daily ROA profitability to accurately monitor capital density. An analysis of total capital and liabilities allows investors to assess the efficiency of R&D investments and borrowed funds, where any sharp fluctuations in the indicator signal a change in the financial stability of this scientific leader.

Competitors of PainReform Ltd. (PRFX)

HLN (haleon.com) - Total Business Assets|Aggregate Company Assets Kenvue KVUE|Total Asset Value of Company Verona Pharma PLC|Jyong Biotech Corp (MENS) - Company Total Assets|Aggregate Asset Value Ligand Corp (LGND)|Company Total Assets AMRX (Amneal Pharmaceuticals)|perrigo.com - Company Total Assets|Aggregate Company Assets Alvotech SA (ALVO)|LQDA: Aggregate Asset Value|GLPG (Galapagos Genomics) - Aggregate Company Assets|ANI Pharmaceuticals Corp (ANIP) - Cumulative Company Assets|MNKD (MannKind Corporation) - Company Total Assets|Company Total Assets amphastar.com (AMPH)|Pacira BioSciences, Inc. (PCRX) - Cumulative Company Assets|Aggregate Asset Value SPRY (ARS Pharmaceuticals Inc)|TBPH: Aggregate Company Assets|AQST - Company Assets|Cumulative Company Assets scPharma SCPH|TECX - Aggregate Business Assets|Company Total Assets Tonix Pharmaceuticals Holding Corp. TNXP|China SXT Pharmaceuticals, Inc. (SXTC) - Aggregate Asset Value|Company Total Assets EPRX (Eupraxia Pharmaceuticals, Inc.)|Company Assets BHST|eXoZymes Inc (EXOZ) - Aggregate Company Assets|Aggregate Asset Value ORMP (oramed.com)|Entera Bio (ENTX) - Aggregate Company Assets|Total Asset Value of Company MindWalk Holdings, Inc. HYFT|ABVC BioPharma Inc - Company Total Assets|CPIX - Company Total Assets|Quantum BioPharma Ltd - Company Total Assets|FGEN (fibrogen.com) - Company Total Asset Base|Aggregate Company Assets Telomir Pharmaceuticals, Inc. (TELO)|Total Business Assets RANI|Synergy CHC Corp (SNYR) - Aggregate Company Assets|Aggregate Asset Value rallybio.com (RLYB)|LEXX: Company Total Assets|Company Assets pulmatrix.com PULM|Company Total Assets Pheton|APM: Total Asset Value of Company|Aggregate Company Assets LYRA|IBO (Impact BioMedical, Inc.) - Company Assets|TNFA - Aggregate Company Assets|Aggregate Asset Value YCBD|Aggregate Company Assets CYTO (Altamira Therapeutics)|Cumulative Company Assets Lipella Pharmaceuticals Inc LIPO|Cumulative Company Assets Optinose|Pieris Pharma - Aggregate Asset Value|PROC - Aggregate Company Assets|petrospharma.com (PTPI) - Aggregate Company Assets|QLI - Cumulative Company Assets|Acelyrin Inc. (SLRN) - Aggregate Business Assets|Company Total Assets TFF Pharma (TFFP)